Cardiovascular magnetic resonance imaging enables comprehensive assessment of cardiovascular function, morphology and pathology. The investigators aim to evaluate the nature and clinical significance of magnetic resonance imaging parameters in patients presenting with first acute ST-elevation myocardial infarction.
Study Type
OBSERVATIONAL
Enrollment
1,500
Cardiovascular magnetic resonance imaging will be performed within the first week after ST-elevation myocardial infarction and in a defined subgroup 4 months, 12 months and 10 years thereafter.
University Hospital for Internal Medicine III (Cardiology and Angiology)
Innsbruck, Austria
RECRUITINGUniversity Hospital for Radiology
Innsbruck, Austria
RECRUITINGOccurence of major adverse cardiovascular events
Time frame: 1 - 5 years
Infarct size assessment (% of left ventricular myocardial mass)
Time frame: baseline, 4 months and 12 months
Assessment of infarct transmurality grade (%) with late gadolinium enhancement imaging
Time frame: baseline, 4 months and 12 months
Occurence and area of microvascular obstruction
Time frame: baseline
Intramyocardial haemorrhage assessed by T2* imaging
Time frame: baseline, 4 months and 12 months
Tissue characterisation by T1, T2 and T2* Mapping
Time frame: baseline, 4 months and 12 months
Myocardial deformation by strain analysis
Time frame: baseline, 4 months and 12 months
Chamber volumes by cine imaging
Time frame: baseline, 4 months and 12 months
Cardiac function by cine imaging
Time frame: baseline, 4 months and 12 months
Stroke volumes by phase contrast imaging
Time frame: baseline, 4 months and 12 months
Aortic pulse wave velocity and distensibility by phase contrast imaging
Time frame: baseline, 4 months and 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Aortic pulse wave distensibility by phase contrast imaging
Time frame: baseline, 4 months and 12 months
Quality of life and invalidity assessment (Global Physical Activity Questionnaire)
Time frame: 1 - 5 years
Biomarker release during the acute and subacute phase
biomarker concentrations of hemodynamic stress (n-terminal pro-B-type natriuretic peptide), neurohumoral markers (i.e. neprilysin ng/ml), inflammatory markers (i.e. procalcitonin µg/l) and markers of myocardial injury (i.e. high sensitivity cardiac troponin T ng/l)
Time frame: baseline, 4 months and 12 months
Parameters of cardiac function by transthoracic echocardiography
Time frame: baseline, 4 months and 12 months
Plaque volume by 3D ultrasound
Time frame: baseline, 12 months
Cardiac autonomic function
Deceleration capacity of heart rate
Time frame: baseline, 4 months and 12 months
Cardiac autonomic function
Heart rate variability
Time frame: baseline, 4 months and 12 months
Cardiac autonomic function
Periodic repolarization dynamics
Time frame: baseline, 4 months and 12 months
Cardiac autonomic function
Baroreflex sensitivity
Time frame: baseline, 4 months and 12 months
Cardiac autonomic function
Skin sympathetic nerve activity
Time frame: baseline, 4 months and 12 months